Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects. Issue 1 (24th September 2015)

• Record Type: Journal Article
• Authors: Tillner, Joachim; Lehmann, Anne; Paehler, Tobias; Lukacs, Zoltan; Ruf, Sven; Sadowski, Thorsten; Pinquier, Jean‐Louis; Ruetten, Hartmut
• Is Part Of: Clinical pharmacology in drug development. Volume 5:Issue 1(2016:Jan./Feb.)
• Page Start: 57
• Page End: 68
• Publication Date: 2015-09-24
• Subjects: cathepsin A -- ß‐galactosidase -- healthy subjects -- first‐in‐man -- renal kallikrein−kinin system; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.201
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: Cathepsin A (CathA) is a lysosomal protein where it forms a stable complex with neuraminidase and ß‐galactosidase. CathA also has enzymatic activity and is involved in the degradation of many peptides. CathA was recently discovered as a target for heart failure, fostering the development of CathA inhibitors with SAR164653 as a frontrunner. The first‐in‐man study investigated single oral doses from 20 to 800 mg of SAR164653 followed by repeat dose studies at doses up to 800 mg in healthy young and elderly subjects. SAR164653 was safe and well tolerated at doses up to 800 mg in healthy subjects, and a maximum tolerated dose could not be determined from the study. Activity of ß‐galactosidase measured in leukocytes did not show any abnormalities. The tmax was 1.0 to 2.5 hours, and the t1/2 was ∼5–11 after single dosing; exposure increased less than dose proportional. Following multiple dosing, accumulation was not observed, Cmax and AUC0–24 increased in a dose‐proportional manner, and t1/2 was around 14–20 hours. The novel CathA inhibitor SAR164653 was found to have a favorable safety profile in these early phase 1 studies, but further studies are required to confirm if SAR164653 is equally safe in patients undergoing long‐term treatment.